CRONOS GROUP INC (CRON.CA) Stock Fundamental Analysis
Canada - TSX:CRON - CA22717L1013 - Common Stock
3.4 CAD
-0.05 (-1.45%)
We assign a fundamental rating of 5 out of 10 to CRON. CRON was compared to 32 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CRON as it has an excellent financial health rating, but there are worries on the profitability. CRON is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CRON was profitable.
CRON had a positive operating cash flow in the past year.
In the past 5 years CRON reported 4 times negative net income.
In the past 5 years CRON reported 4 times negative operating cash flow.
1.2 Ratios
CRON has a better Return On Assets (3.06%) than 84.38% of its industry peers.
CRON's Return On Equity of 3.33% is amongst the best of the industry. CRON outperforms 84.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.06% | ||
| ROE | 3.33% | ||
| ROIC | N/A |
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of CRON (27.27%) is better than 100.00% of its industry peers.
In the last couple of years the Profit Margin of CRON has declined.
Looking at the Gross Margin, with a value of 43.35%, CRON is in line with its industry, outperforming 59.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 27.27% | ||
| GM | 43.35% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.
CRON has more shares outstanding than it did 1 year ago.
CRON has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CRON has an Altman-Z score of 7.38. This indicates that CRON is financially healthy and has little risk of bankruptcy at the moment.
CRON has a Altman-Z score of 7.38. This is amongst the best in the industry. CRON outperforms 96.88% of its industry peers.
There is no outstanding debt for CRON. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.38 |
ROIC/WACCN/A
WACC7.92%
2.3 Liquidity
A Current Ratio of 22.45 indicates that CRON has no problem at all paying its short term obligations.
CRON's Current ratio of 22.45 is amongst the best of the industry. CRON outperforms 100.00% of its industry peers.
A Quick Ratio of 21.28 indicates that CRON has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 21.28, CRON belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 22.45 | ||
| Quick Ratio | 21.28 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 266.67% over the past year.
Measured over the past years, CRON shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -50.78% on average per year.
The Revenue has grown by 19.00% in the past year. This is quite good.
CRON shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.71% yearly.
EPS 1Y (TTM)266.67%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%250%
Revenue 1Y (TTM)19%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%6.06%
3.2 Future
Based on estimates for the next years, CRON will show a very negative growth in Earnings Per Share. The EPS will decrease by -21.14% on average per year.
Based on estimates for the next years, CRON will show a small growth in Revenue. The Revenue will grow by 7.39% on average per year.
EPS Next Y-115.3%
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
EPS Next 5Y-21.14%
Revenue Next Year12.95%
Revenue Next 2Y21.44%
Revenue Next 3Y7.49%
Revenue Next 5Y7.39%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
CRON is valuated rather expensively with a Price/Earnings ratio of 24.29.
CRON's Price/Earnings ratio is a bit cheaper when compared to the industry. CRON is cheaper than 78.13% of the companies in the same industry.
CRON's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 25.56.
A Price/Forward Earnings ratio of 33.96 indicates a quite expensive valuation of CRON.
Based on the Price/Forward Earnings ratio, CRON is valued a bit cheaper than 68.75% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.62. CRON is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.29 | ||
| Fwd PE | 33.96 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
5. Dividend
5.1 Amount
CRON does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:CRON (11/17/2025, 7:00:00 PM)
3.4
-0.05 (-1.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners13.52%
Inst Owner ChangeN/A
Ins Owners6.24%
Ins Owner ChangeN/A
Market Cap1.30B
Revenue(TTM)132.36M
Net Income(TTM)36.10M
Analysts82.86
Price Target2.4 (-29.41%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.4%
Min Revenue beat(2)-4.48%
Max Revenue beat(2)-0.31%
Revenue beat(4)0
Avg Revenue beat(4)-5%
Min Revenue beat(4)-14.99%
Max Revenue beat(4)-0.21%
Revenue beat(8)3
Avg Revenue beat(8)-1.43%
Revenue beat(12)4
Avg Revenue beat(12)-1.97%
Revenue beat(16)6
Avg Revenue beat(16)-3.29%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)100%
EPS NY rev (1m)0%
EPS NY rev (3m)65.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-6.25%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.29 | ||
| Fwd PE | 33.96 | ||
| P/S | 7.02 | ||
| P/FCF | N/A | ||
| P/OCF | 42.69 | ||
| P/B | 0.86 | ||
| P/tB | 0.92 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.14
EY4.12%
EPS(NY)0.1
Fwd EY2.94%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)0.08
OCFY2.34%
SpS0.48
BVpS3.96
TBVpS3.69
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.53
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.06% | ||
| ROE | 3.33% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 27.27% | ||
| GM | 43.35% | ||
| FCFM | N/A |
ROA(3y)-5.62%
ROA(5y)-9.8%
ROE(3y)-5.87%
ROE(5y)-10.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y-62.81%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 209.86% | ||
| Cap/Sales | 20.77% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 22.45 | ||
| Quick Ratio | 21.28 | ||
| Altman-Z | 7.38 |
F-Score6
WACC7.92%
ROIC/WACCN/A
Cap/Depr(3y)70.04%
Cap/Depr(5y)158.35%
Cap/Sales(3y)6.62%
Cap/Sales(5y)22.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)266.67%
EPS 3YN/A
EPS 5Y-50.78%
EPS Q2Q%250%
EPS Next Y-115.3%
EPS Next 2Y-15.5%
EPS Next 3Y3.91%
EPS Next 5Y-21.14%
Revenue 1Y (TTM)19%
Revenue growth 3Y16.47%
Revenue growth 5Y37.71%
Sales Q2Q%6.06%
Revenue Next Year12.95%
Revenue Next 2Y21.44%
Revenue Next 3Y7.49%
Revenue Next 5Y7.39%
EBIT growth 1Y70.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year124.35%
EBIT Next 3Y27.54%
EBIT Next 5Y9.95%
FCF growth 1Y93.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y125.89%
OCF growth 3YN/A
OCF growth 5YN/A
CRONOS GROUP INC / CRON.CA FAQ
What is the fundamental rating for CRON stock?
ChartMill assigns a fundamental rating of 5 / 10 to CRON.CA.
What is the valuation status for CRON stock?
ChartMill assigns a valuation rating of 2 / 10 to CRONOS GROUP INC (CRON.CA). This can be considered as Overvalued.
How profitable is CRONOS GROUP INC (CRON.CA) stock?
CRONOS GROUP INC (CRON.CA) has a profitability rating of 3 / 10.
What is the expected EPS growth for CRONOS GROUP INC (CRON.CA) stock?
The Earnings per Share (EPS) of CRONOS GROUP INC (CRON.CA) is expected to decline by -115.3% in the next year.